JPH06506685A - 新規な非抗凝固剤ヘパリン誘導体 - Google Patents

新規な非抗凝固剤ヘパリン誘導体

Info

Publication number
JPH06506685A
JPH06506685A JP4509700A JP50970092A JPH06506685A JP H06506685 A JPH06506685 A JP H06506685A JP 4509700 A JP4509700 A JP 4509700A JP 50970092 A JP50970092 A JP 50970092A JP H06506685 A JPH06506685 A JP H06506685A
Authority
JP
Japan
Prior art keywords
heparin
periodate
oxidized
nac
antiproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4509700A
Other languages
English (en)
Japanese (ja)
Inventor
コンラッド，エイチ．　エドワード
グオ，ユーチュアン
Original Assignee
グライコメッド　インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グライコメッド　インコーポレイテッド filed Critical グライコメッド　インコーポレイテッド
Publication of JPH06506685A publication Critical patent/JPH06506685A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP4509700A 1991-03-29 1992-03-27 新規な非抗凝固剤ヘパリン誘導体 Pending JPH06506685A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US753,299 1985-07-10
US67740691A 1991-03-29 1991-03-29
US677,406 1991-03-29
US07/753,299 US5280016A (en) 1991-03-29 1991-09-03 Non-anticoagulant heparin derivatives
PCT/US1992/002516 WO1992017187A1 (en) 1991-03-29 1992-03-27 New non-anticoagulant heparin derivatives

Publications (1)

Publication Number Publication Date
JPH06506685A true JPH06506685A (ja) 1994-07-28

Family

ID=27101784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4509700A Pending JPH06506685A (ja) 1991-03-29 1992-03-27 新規な非抗凝固剤ヘパリン誘導体

Country Status (7)

Country Link
US (1) US5280016A (2)
EP (1) EP0577756A1 (2)
JP (1) JPH06506685A (2)
AU (1) AU1763892A (2)
CA (1) CA2107362A1 (2)
NO (1) NO933470L (2)
WO (1) WO1992017187A1 (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000344674A (ja) * 1999-03-31 2000-12-12 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖因子作用の抑制剤及び血管新生の抑制剤
JP2003523460A (ja) * 2000-01-25 2003-08-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 抗脈管形成活性を有し、かつ、抗凝固作用がない、部分脱硫酸グリコサミノグリカンの誘導体
JP2012163560A (ja) * 2011-02-07 2012-08-30 Siemens Healthcare Diagnostics Products Gmbh 直接的凝固因子阻害剤を決定するためのへパリン非感受性方法
JP2015500387A (ja) * 2011-12-19 2015-01-05 ディラフォレッテ アクチエボラゲット 低抗凝固剤ヘパリン

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1994008595A1 (en) * 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
CA2154698C (en) * 1993-01-28 2010-02-23 Lawrence Leroy Kunz Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
AU2435795A (en) * 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
AU5938696A (en) * 1995-06-30 1997-02-05 Zymogenetics Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1999026984A1 (fr) * 1997-11-20 1999-06-03 Ikuo Yamashina Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau
US6498246B1 (en) * 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP2001163932A (ja) * 1999-10-27 2001-06-19 Novartis Ag 材料表面を改質する方法
US20080139503A1 (en) * 2000-01-25 2008-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
CA2420890A1 (en) * 2000-09-08 2002-03-14 Hamilton Civic Hospitals Research Development, Inc. Antithrombotic compositions
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1551852A4 (en) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc METHOD AND PRODUCTS FOR MUCOSAL DELIVERY
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
US7560444B2 (en) * 2003-10-01 2009-07-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
CN104144950B (zh) 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
CN103408677A (zh) * 2013-08-29 2013-11-27 深圳市海普瑞药业股份有限公司 一种抑制细胞增殖的高碘酸氧化的硫酸乙酰肝素
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
GB202217216D0 (en) * 2022-11-17 2023-01-04 Bhogal Pervinder Singh Preparation of medium molecular weight heparin
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620906A (2) *
US3135660A (en) * 1956-11-09 1964-06-02 Riker Laboratories Inc Method for purifying sulfated carbohydrates with oxidizing agents
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
DE3519011A1 (de) * 1985-05-25 1986-11-27 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines materials zur affinitaetschromatographie
US4883751A (en) * 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
AR243204A1 (es) * 1986-11-21 1993-07-30 Ajorca Sa Un metodo para la depolimerizacion quimica de polisacaridos.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000344674A (ja) * 1999-03-31 2000-12-12 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖因子作用の抑制剤及び血管新生の抑制剤
JP2003523460A (ja) * 2000-01-25 2003-08-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 抗脈管形成活性を有し、かつ、抗凝固作用がない、部分脱硫酸グリコサミノグリカンの誘導体
JP2012163560A (ja) * 2011-02-07 2012-08-30 Siemens Healthcare Diagnostics Products Gmbh 直接的凝固因子阻害剤を決定するためのへパリン非感受性方法
JP2015500387A (ja) * 2011-12-19 2015-01-05 ディラフォレッテ アクチエボラゲット 低抗凝固剤ヘパリン

Also Published As

Publication number Publication date
NO933470L (no) 1993-10-19
NO933470D0 (no) 1993-09-28
AU1763892A (en) 1992-11-02
WO1992017187A1 (en) 1992-10-15
CA2107362A1 (en) 1992-09-30
EP0577756A1 (en) 1994-01-12
EP0577756A4 (2) 1994-02-09
US5280016A (en) 1994-01-18

Similar Documents

Publication Publication Date Title
JPH06506685A (ja) 新規な非抗凝固剤ヘパリン誘導体
US5250519A (en) Non-anticoagulant heparin derivatives
CA1171375A (en) Oligosaccharides having selective anticoagulation activity
AU634199B2 (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
EP0983304B1 (en) Dermatan disulfate, an inhibitor of thrombin generation and complement activation
US20190030066A1 (en) Antithrombin-heparin compositions and methods
JPH02502006A (ja) 抗転移活性を有する硫酸化ポリサッカライド
PT94359A (pt) Processo para a preparacao de polissacaridos sulfatados derivados de fucanos de algas castanhas com accao anticoagulante e anticomplementar
JP2001527583A (ja) ヘパリンのｏ−脱硫酸化の制御方法およびそれによって得られる組成物
JPH11506420A (ja) 血栓形成を阻害するための組成物および方法
JP2008518090A (ja) ヘパリン起因性血小板減少症（ｈｉｔ）症候群の硫酸化多糖類治療のための方法および医薬
WO1992002232A1 (en) Heparin fragment showing complement inhibition activity
JPH08508540A (ja) 循環血液量減少性ショックおよび関連ショック症候群の治療のための非抗凝血性の化学修飾したヘパリン様物質
HRP931389A2 (en) Compositions for the regulation of cytokine activity
JPH06506973A (ja) 平滑筋細胞増殖のインヒビターとしての硫酸化多糖類
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
Ventre FROM UNFRACTIONATED HEPARIN TO PENTASACCHARIDE: PARADIGM OF RIGOROUS SCIENCE GROWING IN THE UNDERSTANDING OF THE (-5 (5. THROMBIN GENERATION
Marcum et al. The Biochemistry and Physiology of Anticoagulantly Active Heparin-like